<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095576</url>
  </required_header>
  <id_info>
    <org_study_id>V520-023</org_study_id>
    <secondary_id>2004_091</secondary_id>
    <nct_id>NCT00095576</nct_id>
    <nct_alias>NCT00770549</nct_alias>
  </id_info>
  <brief_title>Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRK AD5 HIV-1 Gag/Pol/Nef) in Adults at High Risk of HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HIV Vaccine Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety and efficacy of an investigational Human Immunodeficiency
      Virus (HIV) vaccine. Efficacy will be measured by either prevention of HIV infection or
      control of HIV viral load in subjects who become HIV infected.

      On September 18, 2007 the Protocol V520-023 DSMB (Data &amp; Safety Monitoring Board) reviewed
      data from a planned interim analysis. These data demonstrated that the investigational
      vaccine candidate was not effective, and all vaccinations in the study were halted.

      Participants were encouraged to continue to come to the clinic for scheduled visits and
      ongoing risk reduction counseling since the vaccine was not effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No further treatment was given in V520-023, however participants were followed. V520-023
      protocol ended earlier than originally planned per protocol and participants (HIV infected
      and uninfected) had the option of participating in an observational long term follow up
      protocol called V520-030/HVTN 504, which served as an extension of V520-023 and would
      continue through the end of 2009.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Adverse Experiences</measure>
    <time_frame>Day 1 to End of Study (Week 210 for HIV uninfected participants and Week 338 for HIV infected participants)</time_frame>
    <description>Number of participants with non-serious AEs with an incidence cut-off of 5% (&gt;5% in at least one treatment group) and number of participants with &gt;1 SAE following administration of study vaccine.
AEs collected include serious and non-serious systemic AEs, and injection-site AEs. All systemic AEs were collected up to 14 days after any vaccine dose, and serious AEs were collected for the entire study period (up to Week 210).
Injection-site AEs are any swelling, redness, pain or tenderness at the injection site. All injection site AEs were collected up to Day 4 after any vaccine dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Adverse Experiences</measure>
    <time_frame>Day 1 to Week 208</time_frame>
    <description>Number of participants with laboratory adverse experiences with an incidence cut-off of 5% (events occurring &gt; 5% in at least one treatment group) following administration of the first dose of study vaccine.
Laboratory AEs were based on a grading system considering the severity of abnormal laboratory values in participants and reflect any unfavorable and unintentional change in function, or chemistry of the body.
All laboratory AEs were collected up to 14 days after any vaccine dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With HIV-1 Infections</measure>
    <time_frame>Day 1 to End of Study (Week 210 for HIV uninfected participants and Week 338 for HIV infected participants)</time_frame>
    <description>The number of participants with HIV-1 infections was to be determined with a periodic HIV-1 screening test to detect antibodies to recombinant HIV-1 envelope protein in the participants' serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV-1 Viral Load in Infected Participants</measure>
    <time_frame>Day 1 to End of Study (Week 210 for HIV uninfected participants and Week 338 for HIV infected participants)</time_frame>
    <description>Plasma HIV-1 viral RNA was to be measured using a ribonucleic acid polymerase chain reaction (RNA PCR) on the last archived sample, and at Weeks 1, 2, 8, 12, and 26 post-HIV-1 infection, and subsequently every 6 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3000</enrollment>
  <condition>AIDS</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Trivalent MRKAd5 HIV-1 gag/pol/nef</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)</intervention_name>
    <description>Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 adenovirus genomes [ad-vg]/dose).
This dose is equivalent to 3x10^10 vp/dose used in study V520-016.</description>
    <arm_group_label>Trivalent MRKAd5 HIV-1 gag/pol/nef</arm_group_label>
    <other_name>V520</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo</intervention_name>
    <description>Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, HIV seronegative adults at high risk of acquiring HIV infection

          -  Cannot have previously received an investigational vaccine

        Exclusion Criteria:

          -  In a monogamous relationship with an HIV-1 seronegative partner for &gt; 1 year

          -  History of anaphylaxis and/or allergy to vaccine components, including Tris buffer,
             MgCl2, and polysorbate 80 (TWEEN)

          -  Received an immune globulin or blood derived products 3 months before injection with
             the first dose of vaccine/placebo or scheduled within 14 days after injection

          -  Previously vaccinated with a live virus vaccine within 30 days before injection with
             the first dose of vaccine or scheduled within 14 days after injection

          -  Previously vaccinated with an inactivated vaccine within 5 days before injection with
             the first dose of vaccine or scheduled within 14 days after injection

          -  Known history of immunodeficiency

          -  History of malignancy (with some exceptions)

          -  Contraindication to intramuscular (IM) injection such as anticoagulant therapy or
             thrombocytopenia

          -  Female subject who is pregnant or breast feeding, or expecting to conceive or donate
             eggs through Week 30 of the study

          -  Male subject who is planning to impregnate or provide sperm donation through Week 30
             of the study

          -  Previously received an investigational HIV vaccine

          -  Has active drug or alcohol abuse or dependence that would interfere with adherence to
             study requirements, or endanger the subject's health while on the study

          -  Has a condition that might endanger the subject's health or interfere with the
             evaluation of the study objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Dominican Republic</country>
    <country>Haiti</country>
    <country>Jamaica</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.</citation>
    <PMID>19012954</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2004</study_first_submitted>
  <study_first_submitted_qc>November 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2004</study_first_posted>
  <results_first_submitted>July 20, 2011</results_first_submitted>
  <results_first_submitted_qc>July 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2011</results_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>3000 participants were enrolled and randomized in the study. However, only 2979 received study vaccination, and are included in the started population.
V520-023 was terminated early based on findings at a planned interim analysis and subjects were encouraged to participate in the V520-030 rollover study for additional long term follow up.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Trivalent MRKAd5 HIV-1 Gag/Pol/Nef</title>
          <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1484"/>
                <participants group_id="P2" count="1495"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>VACCINATED AT VISIT 2 (Dose 1)</title>
              <participants_list>
                <participants group_id="P1" count="1484"/>
                <participants group_id="P2" count="1495"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>VACCINATED AT VISIT 4 (Dose 2)</title>
              <participants_list>
                <participants group_id="P1" count="1426"/>
                <participants group_id="P2" count="1443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>VACCINATED AT VISIT 7 (Dose 3)</title>
              <participants_list>
                <participants group_id="P1" count="1328"/>
                <participants group_id="P2" count="1361"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9">Subjects not completing entire study were eligible for observational long term follow up in V520-030</participants>
                <participants group_id="P2" count="14">Subjects not completing entire study were eligible for observational long term follow up in V520-030</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1475"/>
                <participants group_id="P2" count="1481"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="233"/>
                <participants group_id="P2" count="229"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Option to switch to a rollover study</title>
              <participants_list>
                <participants group_id="P1" count="1097"/>
                <participants group_id="P2" count="1099"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site terminated</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject moved</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trivalent MRKAd5 HIV-1 Gag/Pol/Nef</title>
          <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1484"/>
            <count group_id="B2" value="1495"/>
            <count group_id="B3" value="2979"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" spread="7.8" lower_limit="18" upper_limit="46"/>
                    <measurement group_id="B2" value="30.2" spread="8.13" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B3" value="30.1" spread="7.97" lower_limit="18" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="565"/>
                    <measurement group_id="B2" value="570"/>
                    <measurement group_id="B3" value="1135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="919"/>
                    <measurement group_id="B2" value="925"/>
                    <measurement group_id="B3" value="1844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Adverse Experiences</title>
        <description>Number of participants with non-serious AEs with an incidence cut-off of 5% (&gt;5% in at least one treatment group) and number of participants with &gt;1 SAE following administration of study vaccine.
AEs collected include serious and non-serious systemic AEs, and injection-site AEs. All systemic AEs were collected up to 14 days after any vaccine dose, and serious AEs were collected for the entire study period (up to Week 210).
Injection-site AEs are any swelling, redness, pain or tenderness at the injection site. All injection site AEs were collected up to Day 4 after any vaccine dose.</description>
        <time_frame>Day 1 to End of Study (Week 210 for HIV uninfected participants and Week 338 for HIV infected participants)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trivalent MRKAd5 HIV-1 Gag/Pol/Nef</title>
            <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Adverse Experiences</title>
          <description>Number of participants with non-serious AEs with an incidence cut-off of 5% (&gt;5% in at least one treatment group) and number of participants with &gt;1 SAE following administration of study vaccine.
AEs collected include serious and non-serious systemic AEs, and injection-site AEs. All systemic AEs were collected up to 14 days after any vaccine dose, and serious AEs were collected for the entire study period (up to Week 210).
Injection-site AEs are any swelling, redness, pain or tenderness at the injection site. All injection site AEs were collected up to Day 4 after any vaccine dose.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1484"/>
                <count group_id="O2" value="1495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With non-serious adverse events (NSAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1221"/>
                    <measurement group_id="O2" value="946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With no non-serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                    <measurement group_id="O2" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With no serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1465"/>
                    <measurement group_id="O2" value="1478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Adverse Experiences</title>
        <description>Number of participants with laboratory adverse experiences with an incidence cut-off of 5% (events occurring &gt; 5% in at least one treatment group) following administration of the first dose of study vaccine.
Laboratory AEs were based on a grading system considering the severity of abnormal laboratory values in participants and reflect any unfavorable and unintentional change in function, or chemistry of the body.
All laboratory AEs were collected up to 14 days after any vaccine dose.</description>
        <time_frame>Day 1 to Week 208</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trivalent MRKAd5 HIV-1 Gag/Pol/Nef</title>
            <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Adverse Experiences</title>
          <description>Number of participants with laboratory adverse experiences with an incidence cut-off of 5% (events occurring &gt; 5% in at least one treatment group) following administration of the first dose of study vaccine.
Laboratory AEs were based on a grading system considering the severity of abnormal laboratory values in participants and reflect any unfavorable and unintentional change in function, or chemistry of the body.
All laboratory AEs were collected up to 14 days after any vaccine dose.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1484"/>
                <count group_id="O2" value="1495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With HIV-1 Infections</title>
        <description>The number of participants with HIV-1 infections was to be determined with a periodic HIV-1 screening test to detect antibodies to recombinant HIV-1 envelope protein in the participants' serum.</description>
        <time_frame>Day 1 to End of Study (Week 210 for HIV uninfected participants and Week 338 for HIV infected participants)</time_frame>
        <population>An interim analysis for this study showed that the MRK Ad5 HIV-1 gag/pol/nef vaccine used in this study was not efficacious; therefore, this outcome measure was not analyzed and only a high level summary of the safety data was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent MRKAd5 HIV-1 Gag/Pol/Nef</title>
            <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV-1 Infections</title>
          <description>The number of participants with HIV-1 infections was to be determined with a periodic HIV-1 screening test to detect antibodies to recombinant HIV-1 envelope protein in the participants' serum.</description>
          <population>An interim analysis for this study showed that the MRK Ad5 HIV-1 gag/pol/nef vaccine used in this study was not efficacious; therefore, this outcome measure was not analyzed and only a high level summary of the safety data was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HIV-1 Viral Load in Infected Participants</title>
        <description>Plasma HIV-1 viral RNA was to be measured using a ribonucleic acid polymerase chain reaction (RNA PCR) on the last archived sample, and at Weeks 1, 2, 8, 12, and 26 post-HIV-1 infection, and subsequently every 6 months.</description>
        <time_frame>Day 1 to End of Study (Week 210 for HIV uninfected participants and Week 338 for HIV infected participants)</time_frame>
        <population>An interim analysis for this study showed that the MRK Ad5 HIV-1 gag/pol/nef vaccine used in this study was not efficacious; therefore, this outcome measure was not analyzed and only a high level summary of the safety data was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Trivalent MRKAd5 HIV-1 Gag/Pol/Nef</title>
            <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 Viral Load in Infected Participants</title>
          <description>Plasma HIV-1 viral RNA was to be measured using a ribonucleic acid polymerase chain reaction (RNA PCR) on the last archived sample, and at Weeks 1, 2, 8, 12, and 26 post-HIV-1 infection, and subsequently every 6 months.</description>
          <population>An interim analysis for this study showed that the MRK Ad5 HIV-1 gag/pol/nef vaccine used in this study was not efficacious; therefore, this outcome measure was not analyzed and only a high level summary of the safety data was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Trivalent MRKAd5 HIV-1 Gag/Pol/Nef</title>
          <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1484"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cardiovascular anomaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Hypoplastic left heart syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Unspecified congenital anomaly of heart</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Shunt infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Asbestosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Slipped disc</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Uterine fibroids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Depression aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Depressive episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Manic episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Polysubstance dependence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1484"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1484"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1221" subjects_at_risk="1484"/>
                <counts group_id="E2" subjects_affected="946" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="195" subjects_affected="156" subjects_at_risk="1484"/>
                <counts group_id="E2" events="182" subjects_affected="148" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="114" subjects_affected="94" subjects_at_risk="1484"/>
                <counts group_id="E2" events="87" subjects_affected="75" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="218" subjects_affected="170" subjects_at_risk="1484"/>
                <counts group_id="E2" events="149" subjects_affected="120" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="631" subjects_affected="376" subjects_at_risk="1484"/>
                <counts group_id="E2" events="548" subjects_affected="309" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>General body pain</sub_title>
                <counts group_id="E1" events="98" subjects_affected="76" subjects_at_risk="1484"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="448" subjects_affected="317" subjects_at_risk="1484"/>
                <counts group_id="E2" events="197" subjects_affected="143" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1862" subjects_affected="961" subjects_at_risk="1484"/>
                <counts group_id="E2" events="702" subjects_affected="475" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="511" subjects_affected="337" subjects_at_risk="1484"/>
                <counts group_id="E2" events="149" subjects_affected="115" subjects_at_risk="1495"/>
              </event>
              <event>
                <sub_title>Injection site tenderness</sub_title>
                <counts group_id="E1" events="374" subjects_affected="271" subjects_at_risk="1484"/>
                <counts group_id="E2" events="92" subjects_affected="81" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="734" subjects_affected="461" subjects_at_risk="1484"/>
                <counts group_id="E2" events="631" subjects_affected="394" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="96" subjects_affected="83" subjects_at_risk="1484"/>
                <counts group_id="E2" events="90" subjects_affected="83" subjects_at_risk="1495"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>As this study is part of a multicenter trial, publications derived from this study should include input from the principal investigator, his/her colleagues, the other investigators in this trial, and SPONSOR personnel.
The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The DSMB (Data &amp; Safety Monitoring Board) reviewed interim data which demonstrated that the investigational vaccine was not effective, and all vaccinations were halted. Long term follow up was available for participants in V520-030.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck, Sharp &amp; Dohme</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

